Management also emphasized the importance of CORI deployment. “Other recon” grew 40.8%, and Rogers said 45% of CORI units deployed in the quarter went to ambulatory surgery centers (ASCs). He added that knee growth is 850 basis points higher in accounts where CORI is established, which the company views as evidence of potential upside as utilization expands.Orthopedics delivered 7.9% underlying growth in the quarter, which Rogers said was the strongest quarterly growth for the unit in more than two years. I ...

Financial Performance - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3][15] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Unit Performance - Orthopedics grew 7.9% on an underlying basis, with strong performance in hips and trauma, while U.S. knee growth improved following the launch of LEGION MS [7][8][10] - Sports medicine and ENT grew 7.3%, with joint repair surpassing $1 billion in revenue for the first time, driven by REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8%, with Advanced Wound Care growing 4.4% [13][15] Market Performance - U.S. growth was 5.6%, with other established markets at 7.2% and emerging markets at 6.4% [7] - Excluding China, underlying growth was 7.2%, indicating strong performance across various regions [16] Company Strategy and Industry Competition - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][35] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth for 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC to 8.3% [6][25] - The company plans to maintain a dividend ratio of 35%-40% and consider buybacks subject to leverage targets [27] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with innovation contributing significantly to this growth [48][49] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and the impact of VBP will be less significant moving forward [64][75] Question: How does M&A impact bottom line growth? - Management emphasized that M&A, such as the acquisition of Integrity, is aimed at scaling in areas of strength and is expected to be accretive in the long term [68][69]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported underlying revenue growth of 5.3%, with all three business units growing by over 5% [1][15] - Free cash flow increased to $840 million, a 52.5% year-on-year growth, enabling a $500 million share buyback program [3][26] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] Business Line Data and Key Metrics Changes - Orthopedics grew 7.9% on an underlying basis, with strong performance in hips and trauma, while U.S. knee growth improved following the launch of LEGION MS [8][9] - Sports medicine and ENT grew 7.3%, driven by double-digit growth in joint repair, surpassing $1 billion in revenue for the first time [12][13] - Advanced Wound Management grew 2.8%, with Advanced Wound Care growing 4.4% [14][15] Market Data and Key Metrics Changes - U.S. growth was 5.6%, other established markets grew 7.2%, and emerging markets grew 6.4% [7] - Excluding China, underlying growth was 7.2%, indicating strong performance in other markets despite challenges in China [16][17] Company Strategy and Development Direction - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][35] - The company aims for more than 20% margin in orthopedics by 2030, supported by initiatives like the Ortho360 operating model [3][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth for 2026, with trading profit growth expected to be around 8% [4][28] - The impact of China VBP is expected to be less significant in 2026, with management anticipating a flat performance in greater China sales compared to 2025 [70][73] - The company is focused on innovation, with over 60% of growth in 2025 coming from products launched in the last five years [2][16] Other Important Information - The company achieved a 240 basis points trading margin expansion from 17.3% in 2022 to 19.7% in 2025, despite facing headwinds from VBP in China and inflation [5][19] - The company plans to maintain a dividend ratio of 35%-40% and consider buybacks subject to leverage targets [27] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and the impact of new product launches? - Management indicated that growth will be driven by multiple sources, with innovation contributing significantly, and expects around 6% growth for 2026 [48][49] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and they expect a balanced portfolio to drive growth without the previous VBP drag [63][74] Question: How does M&A impact bottom line growth? - Management emphasized that M&A, like the acquisition of Integrity, is aimed at scaling in areas of strength and will complement existing products, enhancing overall growth potential [66][68]

Summary of Smith & Nephew Capital Markets Day 2025 Company Overview - **Company**: Smith & Nephew (NYSE: SNN) - **Industry**: Medical Technology - **Event**: Capital Markets Day 2025 - **Date**: December 08, 2025 Key Points and Arguments New Strategy: RISE - Smith & Nephew introduced a new strategy called RISE aimed at achieving 6%-7% organic growth and 9%-10% trading profit growth over the next three years [3][4][21] - The strategy focuses on reaching more patients, innovating to enhance care standards, scaling through strategic investments, and executing efficiently [22] Financial Targets - Expected free cash flow to reach $1 billion by 2028 [4][35] - Return on Invested Capital (ROIC) projected to improve to 12%-13% by 2028 [4][35] - Trading margin expanded from 17.3% in 2022 to at least 19.5% in 2025 [19] Market Position and Growth Potential - Addressable market exceeds $50 billion, growing at approximately 6% [7] - Smith & Nephew is the second-largest player in the global Sports Medicine market valued at $7 billion and the second-largest in the global wound market worth $13 billion [7][9] - The company has a diversified portfolio with over 50% of revenues from the U.S. and nearly a third from developed international markets [9] Product Innovations - Key products include REGENETEN for tendon repair, AGILI-C for cartilage repair, PICO for negative pressure wound therapy, and CORI for robot-assisted orthopedic surgery [25][26] - More than 75 product launches in the last five years, contributing significantly to revenue growth [39] Operational Improvements - Implementation of a 12-Point Plan to address operational inefficiencies, including closing five manufacturing facilities and improving inventory alignment [12][14] - Transition to a simpler business unit structure to enhance accountability and decision-making [15][16] Focus on Cash and Cost Management - Achieved an 8% reduction in central costs and initiated a $200 million savings program [17] - Aiming for gross cost benefits of $325-$375 million, with significant savings expected from manufacturing and procurement [18] Innovation and R&D - Continued investment in R&D, maintaining around 5% of revenue, with plans to increase investment in 2026 [38] - Focus on two key innovation platforms: MTEC (musculoskeletal technologies) and biologics, aimed at enhancing surgical outcomes and patient care [40][42] M&A Strategy - Strategic focus on high-returning, high-growth opportunities, with recent successful acquisitions like CartiHeal [29] - New leadership in corporate strategy to drive M&A efforts aligned with the company's strengths [29] Patient-Centric Approach - Emphasis on improving patient outcomes and experiences through innovative products and technologies [55] - Commitment to addressing unmet needs in healthcare, enhancing the quality of life for patients [56] Additional Important Insights - The company aims to increase patient reach from 15 million to 20 million by 2028 [23] - The sports medicine market is valued at $6.6 billion, with a focus on minimally invasive procedures and rapid recovery [57] - Smith & Nephew has a strong track record of innovation, with many products becoming industry standards [58] This summary encapsulates the key points discussed during the Smith & Nephew Capital Markets Day 2025, highlighting the company's strategic direction, financial targets, market position, product innovations, operational improvements, and commitment to patient care.